Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
4,789
Views
3
CrossRef citations to date
0
Altmetric
Neurology
Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia
Michael L. Ganza Real-world Evidence, Evidera, Waltham, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9702-2999
, https://orcid.org/0000-0002-9702-2999
Ameya Chavanb Evidence Synthesis, Modeling & Communication, Evidera, Bethesda, MD, USA
, Rahul Dhandac Neurocrine Biosciences, Inc, San Diego, CA, USAhttps://orcid.org/0000-0002-6941-3853
, Michael Serbinc Neurocrine Biosciences, Inc, San Diego, CA, USAhttps://orcid.org/0000-0001-6876-7150
& Charles Yonanc Neurocrine Biosciences, Inc, San Diego, CA, USA
Pages 103-113
|
Received 17 Sep 2020, Accepted 09 Dec 2020, Published online: 20 Jan 2021
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.